Abstract: The invention relates to a liquid-cooled internal combustion engine (1), comprising: —a cylinder head (2) having a top-down cooling concept, with a head cooling chamber (15) with a first head partial cooling chamber (16) spaced apart from the fire deck (4) and with a second head partial cooling chamber (17), which adjoins the fire deck (4) of the cylinder head (2) and is separated from the first head partial cooling chamber (16) by an intermediate deck (18), the first head partial cooling chamber (16) and the second head partial cooling chamber (17) being fluidically interconnected, in the region of a central component (19), by means of a passage channel (21) in the intermediate deck (18); —a main feed channel (32), which is disposed in the cylinder block (3) and is connected to the first head partial cooling chamber (16) by means of a first flow passage (34) in the fire deck (4) of the cylinder head (2) and by means of a supply channel (35); —a block cooling jacket (41), which is fluidically connected to the

Abstract: Insulin-like growth factor I (IGF I) and pharmaceutical compositions comprising IGF I are useful in improving glomerular filtration and renal plasma flow and can be used for the treatment of patients suffering from renal diseases and for the preparation of therapeutic combinations for treatment of renal diseases.

Abstract: An electrical hand tool, powered by a battery, for use as a screwdriver or drill, is provided with a subcompartment 19 for the battery 20. The housing 1 consists of a drive compartment 2 and a handle component 3. In order to construct a compartment 18 for the battery 20 which is relatively large, without making the handle compartment 3 correspondingly long, a subcompartment 19 is provided in the drive component 2. The switch 8 is mounted on the drive component 2 between the subcompartment 19 and the tool receptacle 6.

Abstract: The invention concerns a method for treating and preventing secondary effects of hyperinsulinemia by application of insulin-like growth factor I (IGF I), and pharmaceutical compositions comprising IGF I which are useful for this purpose.